SEARCH

SEARCH BY CITATION

References

  • 1
    Farrell RJ, Kelly CP. Celiac sprue—current concepts. N Engl J Med 2002; 346: 180188.
  • 2
    Hu WT, Murray JA, Greenaway MC, Parisi JE, Josephs KA. Cognitive impairment and celiac disease. Arch Neurol 2006; 63: 14401446.
  • 3
    Zone JJ. Skin manifestations of celiac disease. Gastroenterology 2005; 128( Suppl 1): S87S89.
  • 4
    Frustaci A, Cuoco L, Chimenti C, Pieroni M, Fioravanti G, Gentiloni N, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105: 26112618.
  • 5
    Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131: 19812002.
  • 6
    Hagander B, Brandt L, Sjolund K, Berg NO, Norden A, Sjolund K, et al. Hepatic injury in adult celiac disease. Lancet 1977; 2: 270272.
  • 7
    Bardella MT, Franquelli M, Quatrini M, Molteni N, Bianchi P, Conte D. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. HEPATOLOGY 1995; 22: 833836.
  • 8
    Bonamico M, Pitzalis G, Culasso F, Vania A, Monti S, Benedetti C, et al. Hepatic damage during celiac disease in childhood. Minerva Pediatr 1986; 38: 959963.
  • 9
    Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi F. Celiac disease hidden by cryptogenic hypertransaminasemia. Lancet 1998; 352: 2629.
  • 10
    Bardella MT, Vecchi M, Conte D, Del Ninno E, Franquelli M, Pacchetti S, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. HEPATOLOGY 1999; 29: 654657.
  • 11
    Lindgren S, Sjoberg K, Eriksson S. Unsuspected celiac disease in chronic ‘cryptogenic’ liver disease. Scand J Gastroenterol 1994; 29: 661664.
  • 12
    Ludvigsson JF, Elfstrom P, Broome U, Ekbom A, Montgomery SM. Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol 2007; 5: 6369.
  • 13
    Peters U, Askling J, Gridley G, Ekbom A, Linet M. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 2003; 163: 15661572.
  • 14
    Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123: 13671384.
  • 15
    Clemente MG, De Virgiliis S, Kang JS, Macatagney R, Musu MP, Di Pierro MR, et al. Early effects of gliadin on enterocyte intracellular signaling involved in intestinal barrier function. Gut 2003; 52: 218223.
  • 16
    Novacek G, Miehsler W, Wrba F, Ferenci P, Penner E, Vogelsang H. Prevalence and clinical importance of hypertransaminasemia in celiac disease. Eur J Gastroenterol Hepatol 1999; 11: 283288.
  • 17
    Volta U, Granito A, De Franceschi L, Petrolini N, Bianchi FB. Anti tissue transglutaminase antibodies as predictors of silent celiac disease in patients with hypertransaminasemia of unknown origin. Dig Liver Dis 2001; 33: 420425.
  • 18
    Pelaez-Luna M, Schmulson M, Robles-Diaz G. Intestinal involvement is not sufficient to explain hypertransaminasemia in celiac disease? Med Hypotheses 2005; 65: 937941.
  • 19
    Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Kiraly R, Kovacs JB, et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by celiac autoantibodies. Gut 2004; 53: 641648.
  • 20
    Demir H, Yuce A, Caglar M, Kale G, Kocak N, Ozen H, et al. Cirrhosis in children with celiac disease. J Clin Gastroenterol 2005; 39: 630633.
  • 21
    Kaukinen K, Halme L, Collin P, Farkkila M, Maki M, Vehmanen P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002; 122: 881888.
  • 22
    Sharma BC, Bhasin DK, Nada R. Association of celiac disease with non-cirrhotic portal fibrosis. J Gastroenterol Hepatol 2006; 21(pt 2): 332334.
  • 23
    Jacobsen MB, Fausa O, Elgjo K, Schrumpf E. Hepatic lesions in adult celiac disease. Scand J Gastroenterol 1990; 25: 656662.
  • 24
    Fraquelli M, Colli A, Colucci A, Bardella MT, Trovato C, Pometta R, et al. Accuracy of ultrasonography in predicting celiac disease. Arch Intern Med 2004; 164: 169174.
  • 25
    Bartusek D, Valek V, Husty J, Uteseny J. Small bowel ultrasound in patients with celiac disease: retrospective study. Eur J Radiol 2007. DOI:10.1016/j.ejrad.2007.01.28. Available at: http://www.sciencedirect.com.
  • 26
    Rettenbacher T, Hollerweger A, Macheiner P, Huber S, Gritzmann N. Adult celiac disease: US signs. Radiology 1999; 211: 389394.
  • 27
    Pollock DJ. The liver in celiac disease. Histopathology 1997; 1: 421430.
  • 28
    Maggiore G, Caprai S. The liver in celiac disease. J Pediatr Gastroenterol Nutr 2003; 37: 117119.
  • 29
    Logan RF, Fergusson A, Finlayson ND, Weir DG. Primary biliary cirrhosis and celiac disease: an association? Lancet 1978; 1: 230233.
  • 30
    Dickey W, McMillan S, Callender M. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J Clin Gastroenterol 1997; 25: 328329.
  • 31
    Kingham JGC, Parker DR. The association between primary biliary cirrhosis and celiac disease: a study of relative prevalences. Gut 1998; 42: 120122.
  • 32
    Gillet HR, Cauch-Dudek K, Jenny E, Heathcote EJ, Freeman HJ. Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis. Can J Gastroenterol 2000; 14: 672675.
  • 33
    Floreani A, Betterle C, Baragiotta A, Martini S, Venturi C, Basso D, et al. Dig Liver Dis 2002; 34: 248250.
  • 34
    Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002; 97: 26092613.
    Direct Link:
  • 35
    Chatzicostas C, Roussomoustakaki M, Srygiannakis D, Niniraki M, Tzardi M, Koulentaki M, et al. Primary biliary cirrhosis and autoimmune cholangitis are not associated with celiac disease in Crete. BMC Gastroenterol 2002; 2: 5.
  • 36
    Bardella MT, Quantrini M, Zuin M, Podda M, Cesarini L, Velio P, et al. Screening patients with celiac disease for primary biliary cirrhosis and vice versa. Am J Gastroenterol 1997; 92: 15241526.
  • 37
    Niveloni S, Dezi R, Pedreira S, Podesta A, Cabanne A, Vazquez H, et al. Gluten sensitivity in patients with primary biliary cirrhosis. Am J Gastroenterol 1998; 93: 404408.
    Direct Link:
  • 38
    Sorensen HT, Thulstrup AM, Blomqvist P, Norgaard B, Fonager K, Ekbom A. Risk of primary biliary liver cirrhosis in patients with celiac disease: Danish and Swedish cohort study. Gut 1999; 44: 736738.
  • 39
    Lawson A, West J, Aithal GP, Logan RFA. Autoimmune cholestatic liver disease in people with celiac disease: a population-based study of their association. Aliment Pharmacol Ther 2005; 21: 401405.
  • 40
    Gogos CA, Nikolopoulou V, Zolota V, Siampi V, Vagenakis A. Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J Hepatol 1999; 30: 321324.
  • 41
    Feld JJ, Meddings J, Heathcote EJ. Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci 2006; 51: 16071613.
  • 42
    Selmi C, Gershwin ME. Bacterial and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol 2004; 16: 406410.
  • 43
    Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97: 397406.
  • 44
    Murray JA, Watson T, Clearman B, Mitros F. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr 2004; 79: 669673.
  • 45
    West J, Logan RFA, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with celiac disease: population based cohort study. BMJ 2004; 329: 716720.
  • 46
    Volta U, DeFranceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998; 43: 21902195.
  • 47
    Villalta D, Girolami D, Bidoli E, Bizarro N, Tampoia M, Liguori M, et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue transglutaminase autoantibodies. J Clin Lab Anal 2005; 19: 610.
  • 48
    Klein J, Sato A. The HLA system (first of two parts). N Engl J Med 2000; 343: 702709.
  • 49
    Tollefsen S, Arentz-Hansen H, Fleckenstein B, Molberg O, Raki M, Kwok WW, et al. HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. J Clin Invest 2006; 116: 22262236.
  • 50
    Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 5466.
  • 51
    Smyth C, Kelleher D, Keeling PWN. Hepatic manifestations of gastrointestinal diseases: inflammatory bowel disease, celiac disease, and Whipple's disease. Clin Liver Dis 2002; 6: 10131032.
  • 52
    Hay JE, Wiesner RH, Shorter RG, LaRusso NF, Baldus WP. Primary sclerosing cholangitis and celiac disease. A novel association. Ann Intern Med 1988; 109: 713717.
  • 53
    Fracassetti O, Delvecchio G, Tambini R, Loernzi N, Gavazzeni G. Primary sclerosing cholangitis with celiac sprue: two cases. J Clin Gastroenterol 1996; 22: 7172.
  • 54
    Yang A, Chen Y, Scherl E, Neugut AI, Bhagat G, Green PHR. Inflammatory bowel disease in patients with celiac disease. Inflamm Bowel Dis 2005; 11: 528532.
  • 55
    Di Tola M, Sabbatella L, Anania MC, Viscido A, Caprilli R, Pica R, et al. Anti-tissue transglutaminase in inflammatory bowel disease: new evidence. Clin Chem Lab Med 2004; 42: 10921097.
  • 56
    Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 459469.
  • 57
    Boberg KM, Spurkland A, Rocca G, Egeland T, Saarinen S, Mitchell S, et al. The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001; 8: 886890.
  • 58
    Fine KD, Ogunji F, Saloum Y, Beharry S, Crippin J, Weinstein J. Celiac sprue: another autoimmune syndrome associated with hepatitis C. Gastroenterology 2001; 96: 138145.
  • 59
    Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol 2004; 38: 901905.
  • 60
    Thevenot T, Boruchowicz A, Henrion J, Nalet B, Moindrot H, and ANGH. Celiac disease is not associated with chronic hepatitis C. Dig Dis Sci 2007; 52: 13101312.
  • 61
    Bardella MT, Marino R, Meroni PL. Celiac disease during interferon treatment. Ann Inter Med 1999; 131: 157158.
  • 62
    Cammarota G, Cuoco L, Cianci R, Pandolfi F, Gasbarrini G. Onset of celiac disease during treatment with interferon for chronic hepatitis C. Lancet 2000; 356: 14941495.
  • 63
    Narvaez I, Perez B, Alcalde M, Jimenez C, Soria A. Chronic viral hepatitis, interferon, diabetes mellitus, and celiac disease. Am J Gastroenterol 2003; 98: 23362337.
    Direct Link:
  • 64
    Adinolfi LE, Mangoni-Durante E, Andreana A. Interferon and ribavirin treatment of chronic hepatitis C may activate celiac disease. Am J Gastroenterol 2001; 96: 607608.
    Direct Link:
  • 65
    Monteleone G, Pender SL, Wathen NC, MacDonald TT. Interferon-α drives T cell-mediated immunopathology in the intestine. Eur J Immunol 2001; 31: 22472255.
  • 66
    Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, et al. Ribavirin polarizes human T cell response toward a type 1 cytokine profile. J Hepatol 1999; 30: 376382.
  • 67
    Noh KW, Poland GA, Murray JA. Hepatitis B vaccine nonresponse and celiac disease. Am J Gastroenterol 2003; 98: 22892292.
    Direct Link:
  • 68
    Park S-D, Markowitz J, Pettei M, Weinstein T, Sison CP, Swiss SR, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr 2007; 44: 431435.
  • 69
    Turcu A, Leveque L, Bielefeld P, Besancenot JF, Hillon P. Adult celiac disease and hemochromatosis. Am J Gastroenterol 2000; 95: 36613662.
    Direct Link:
  • 70
    Heneghan MA, Feeley KM, Stevens FM, Little MPG, McCarthy CF. Precipitation of iron overload and hereditary hemochromatosis after successful treatment of celiac disease. Am J Gastroenterol 2000; 95: 298300.
    Direct Link:
  • 71
    Butterworth JR, Cooper BT, Rosenberg WMC, Purkiss M, Jobson S, Hathaway M, et al. The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology 2002; 123: 444449.
  • 72
    Barisani D, Ceroni S, Del Bianco S, Meneveri R, Bardella MT. Hemochromatosis gene mutations and iron metabolism in celiac disease. Haematologica 2004; 89: 12991305.
  • 73
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 12211231.
  • 74
    Bardella MT, Valenti L, Pagliari C, Peracchi M, Fare M, Fracanzani AL, et al. Searching for celiac disease in patients with non-alcoholic fatty liver disease. Dig Liver Dis 2004; 36: 333336.
  • 75
    Loiacono O, Petta S, Venezia G, DiMarco V, Tarantino G, Barbaria F, et al. Anti-tissue transglutaminase antibodies in patients with abnormal liver test: is it always celiac disease? Am J Gastroenterol 2005; 100: 24722477.
    Direct Link:
  • 76
    Low-Beer TS, Harvey RF, Davies ER, Read AF. Abnormalities of serum cholecystokinin and gallbladder emptying in celiac disease. N Engl J Med 1975; 292: 961963.
  • 77
    DiMagno EP, Go WLW, Summerskill WHJ. Impaired cholecystokinin-pancreozymin secretion, intraluminal dilution and maldigestion of fat in sprue. Gastroenterology 1972; 63: 2532.
  • 78
    Maton PN, Selden AC, Fitzpatrick ML, Chadwick VS. Defective gallbladder emptying and cholecystokinin release in celiac disease. Reversal by gluten-free diet. Gastroenterology 1985; 88: 391396.
  • 79
    Fraquelli M, Bardella MT, Peracchi M, Cesana BM, Bianchi PA, Conte D. Gallbladder emptying and somatostatin and cholecystokinin plasma levels in celiac disease. Am J Gastroenterol 1999; 94: 18661870.
    Direct Link:
  • 80
    Patel RS, Johlin FC, Murray JA. Celiac disease and recurrent pancreatitis. Gastrointest Endosc 1999; 50: 823827.
  • 81
    Buess M, Steuerwald M, Wegmann W, Rothen M. Obstructive jaundice caused by enteropathy-associated T-cell lymphoma in a patient with celiac disease. J Gastroenterol 2004; 39: 11101113.
  • 82
    Sjoberg K, Lindgren S, Eriksson S. Frequent occurrence of non-specific gliadin antibodies in chronic liver disease. Endomysial but no gliadin antibodies predict celiac disease in patients with chronic liver disease. Scand J Gastroenterol 1997; 32: 11621167.
  • 83
    Carroccio A, Giannitrapani L, Soresi M, Not T, Iacono G, DiRosa C, et al. Guinea pig transglutaminase immunolinked assay does not predict celiac disease in patients with chronic liver disease. Gut 2001; 49: 506511.
  • 84
    Vecchi M, Folli C, Donato MF, Formenti S, Arosio E, DeFranchis R. High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source. Scand J Gastroenterol 2003; 38: 5054.
  • 85
    Villalta D, Crovatto M, Stella S, Tonutti E, Tozzoli R, Bizzaro N. False positive reactions for IgA and IgG anti-tissue transglutaminase antibodies in liver cirrhosis are common and method-dependent. Clin Chim Acta 2005; 356: 102109.
  • 86
    Murray JA, Herlein J, Mitros F, Goeken JA. Serologic testing for celiac disease in the United States: results of a multilaboratory comparison study. Clin Diagn Lab Immunol 2000; 7: 584587.
  • 87
    Kaukinen K, Partanen J, Maki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol 2002; 97: 695699.
    Direct Link:
  • 88
    Sollid LM, Lie BA. Celiac disease genetics: current concepts and practical applications. Clin Gastroenterol Hepatol 2005; 3: 843851.